Literature DB >> 6786

Studies on adrenal phenylethanolamine N- methyltransferase (PNMT) with S K & F 64139, a selective inhibitor.

R G Pendleton, C Kaiser, G Gessner.   

Abstract

SK&F 64139 is a potent, reversible inhibitor of phenylethanolamine N-methyltransferase; its IC50 concentration in our standard assay system was 1 X 10(-7) M. Kinetically, the compound is a competitive inhibitor with respect to norepinephrine but is uncompetitive when S-adenosylmethionine is the variable substrate. In contrast to a previously reported compound (SK&F 7698), the drug is only a weak alpha receptor antagonist (KB = 6 X 10(-6) M). In both the rat and squirrel monkey, SK&F 64139 produced dose-dependent decreases in the adrenal epinephrine content coupled with stoichiometrically equivalent increases in the norepinephrine pool(s). Further evidence for in vivo phenylethanolamine N-methyltransferase inhibitory activity was that the drug markedly inhibited the conversion of a tracer dose of 3H-norepinephrine to 3H-epinephrine in the rat adrenal gland after unit oral doses as low as 5 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6786

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  The effects of an inhibitor of phenylethanolamine N-methyltransferase upon stimulated adrenal catecholamine release and excretion in the rat.

Authors:  R G Pendleton; G Weiner; B Jenkins; G Gessner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-04       Impact factor: 3.000

2.  Application of the Goldilocks effect to the design of potent and selective inhibitors of phenylethanolamine N-methyltransferase: balancing pKa and steric effects in the optimization of 3-methyl-1,2,3,4-tetrahydroisoquinoline inhibitors by beta-fluorination.

Authors:  Gary L Grunewald; Mitchell R Seim; Jian Lu; Mariam Makboul; Kevin R Criscione
Journal:  J Med Chem       Date:  2006-05-18       Impact factor: 7.446

3.  Transition-State Analogues of Phenylethanolamine N-Methyltransferase.

Authors:  Niusha Mahmoodi; Rajesh K Harijan; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2020-08-07       Impact factor: 15.419

4.  Inhibition of phenylethanolamine-N-methyltransferase and brain-stimulated reward.

Authors:  R J Katz; B J Carroll
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

5.  Studies on the characterization and inhibition of rat brain phenylethanolamine N-methyltransferase.

Authors:  R G Pendleton; J Khalsa; G Gessner; J Sawyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

6.  Studies on the long term effects of SK&F 29661 upon adrenal catecholamines.

Authors:  R G Pendleton; G Gessner; J Sawyer; L Hillegass; D A Miller
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-04       Impact factor: 3.000

7.  The long term effects of an inhibitor of phenylethanolamine N-methyltransferase upon adrenal epinephrine biosynthesis.

Authors:  R G Pendleton; G Gessner; B Jenkins
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-11       Impact factor: 3.000

8.  Synthesis of 4,5,6,7-tetrahydrothieno[3,2-c]pyridines and comparison with their isosteric 1,2,3,4-tetrahydroisoquinolines as inhibitors of phenylethanolamine N-methyltransferase.

Authors:  Gary L Grunewald; Mitchell R Seim; Seema R Bhat; Marc E Wilson; Kevin R Criscione
Journal:  Bioorg Med Chem       Date:  2007-10-11       Impact factor: 3.641

9.  Studies on lung N-methyltransferases, a pharmacological approach.

Authors:  R G Pendleton; G Gessner; J Sawyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

10.  The influence of SK & F 64139, a phenylethanolamine-N-methyltransferase inhibitor, on centrally mediated cardiovascular effects of alpha-methyldopa and clonidine.

Authors:  M Gerold; G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.